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Background: Trypanothione reductase (TR) helps to maintain an intracellular
reducing environment in trypanosomatids, a group of protozoan parasites that
afflict humans and livestock in tropical areas. This protective function is
achieved via reduction of polyamine–glutathione conjugates, in particular
trypanothione. TR has been validated as a chemotherapeutic target by
molecular genetics methods. To assist the development of new therapeutics,
we have characterised the structure of TR from the pathogen Trypanosoma
cruzi complexed with the substrate trypanothione and have used the structure
to guide database searches and molecular modelling studies.
Results: The TR–trypanothione-disulfide structure has been determined to
2.4 Å resolution. The chemical interactions involved in enzyme recognition and
binding of substrate can be inferred from this structure. Comparisons with the
related mammalian enzyme, glutathione reductase, explain why each enzyme is
so specific for its own substrate. A CH•••O hydrogen bond can occur between
the active-site histidine and a carbonyl of the substrate. This interaction
contributes to enzyme specificity and mechanism by producing an electronic
induced fit when substrate binds. Database searches and molecular modelling
using the substrate as a template and the active site as receptor have identified
a class of cyclic-polyamine natural products that are novel TR inhibitors.
Conclusions: The structure of the TR–trypanothione enzyme–substrate
complex provides details of a potentially valuable drug target. This information
has helped to identify a new class of enzyme inhibitors as novel lead
compounds worthy of further development in the search for improved medicines
to treat a range of parasitic infections.
Introduction
Protozoa belonging to the order Kinetoplastida, suborder
Trypanosomatina, are the causal agents of a variety of
tropical diseases that pose an important medical and eco-
nomic problem for millions of people. Chagas’ disease,
caused by infection with Trypanosoma cruzi, is a particular
problem in South and Central America [1]. There are no
appropriate vaccines and the current therapies for trypano-
somal infection are inadequate because of the low effi-
cacy and high toxicity of the available drugs. The problem
is compounded by the ability of the parasites to develop
drug resistance — hence the urgent search for new and
improved anti-trypanosomal agents [2]. One way forward
is structure-based drug development [3,4]. In this approach
a valid biochemical target, an enzyme or a metabolic
pathway, is identified and characterised with respect to
structure and function. The molecular detail is then used
to support a search for enzyme inhibitors or protein ligands.
Trypanothione reductase (TR) represents one such target
for anti-trypanosomal drug development and an under-
standing of the enzyme is necessary to facilitate a search
for inhibitors with the desired pharmacological properties.
Living cells rely on two classes of low molecular mass
chemicals, polyamines and thiol-containing compounds, in
a wide range of biological functions. Amongst others,
polyamines are implicated in protein synthesis, cell growth
and development [5], whereas the peptide glutathione 
(L-γ-glutamyl-L-cysteinylglycine; Figure 1a) is involved in
maintaining redox balance and regulating diverse aspects of
metabolism [6]. The thiol form of glutathione, GSH, func-
tions as a protective agent, maintaining an intracellular
reducing environment. GSH is oxidised to glutathione
disulfide (GSSG) following reaction with potentially dam-
aging radicals and oxidants. The enzyme glutathione reduc-
tase (GR) ensures that high thiol levels are preserved by
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catalysing the reduction of the disulfide. The GR–GSSG
system has been thoroughly investigated by a variety of
techniques, including crystallography [7].
Trypanosomatids use polyamine-glutathione adducts, instead
of GSH, to function in similar protective and regulatory
roles [8]. Three adducts have been identified so far: trypan-
othione (N1,N8-bis(glutathionyl)spermidine; Figure 1b), gluta-
thionylspermidine and homotrypanothione [8]. Similarities
with glutathione suggested that these metabolites might
have a similar biological function in scavenging free radicals
and oxygen-reactive species formed by metabolic processes
or when the parasites are subjected to oxidative stress by
the host immune response. The adducts can also regulate
polyamine levels and thereby influence cell growth and
development. Trypanosomes contain low levels of gluta-
thione but do not possess GR. The enzyme trypanothione
reductase is responsible for the conversion of trypanothione
disulfide (T[S]2) to the di-thiol form, dihydrotrypanothione
(T[SH]2). The di-thiol form can reduce GSSG to GSH by
thiol–disulfide exchange [8]. Human GR and TR are both
NADPH-dependent, flavin-containing disulfide oxidore-
ductases. They function as homodimers of subunit molecu-
lar mass in the range 52–54 kDa and share about 30%
sequence identity. The key residues involved in catalysis
are conserved but the critical observation has been made
that each enzyme is specific for its cognate substrate,
despite mechanistic and structural similarities [8,9]. This
indicates that it should be possible to inhibit the parasite
TR but not the human host GR. Furthermore, molecular
genetic studies indicate that TR is essential for growth and
survival of the parasites [10–12]. This validates TR and try-
panothione metabolism as a target for structure-based drug
design against trypanosomatids; one of only a few systems
where such validation has been achieved. A complete under-
standing of the structure and reactivity of TR is required to
support such an approach. 
Previous studies provided clues about the roles of various
amino acids with respect to enzyme specificity [3,7,13].
The early crystallographic research used TR from the
non-pathogenic Crithidia fasciculata [14–16]. We decided
to concentrate on T. cruzi TR because it represents the
direct target for which new chemotherapeutic agents are
sought, and therefore determined the structure at 2.3 Å
resolution [17]. We now report the structure of TR in
complex with the physiological substrate T[S]2. This
structure provides, for the first time, direct evidence of
how the target enzyme interacts with this physiological
substrate and explains why TR and GR are specific for
their own substrates. Comparisons of disulfide oxidore-
ductases and serine proteases suggest that these two types
of enzyme share similarities in their mechanism. The
determination of the T[S]2 conformation in the TR active
site provides molecular templates to direct the identifica-
tion of enzyme inhibitors by combining database searches
and molecular modelling methods. Our successful utilisa-
tion of the structure in this way has lead to the discovery
of a novel class of enzyme inhibitors.
Results and discussion
Structure of TR and location of the active site
The architecture of the TR dimer, the location of cofactor-
binding domains and the substrate-binding sites are pre-
sented in Figure 2. Each subunit comprises an FAD-
binding domain, an NADPH-binding domain and an inter-
face domain, the latter of which is responsible for the assem-
bly of the homodimer. The disulfide-substrate-binding site
is ~15 Å wide and deep, 20 Å in length and is formed by
residues from the FAD-binding domain and the interface
domain of the partner subunit. This cleft is created by
residues 15–22, 53–62, 103–114 and 335–343 from one sub-
unit and 396′–399′ and 461′–470′ from the other (where ′
indicates a residue from the partner subunit). The residues
involved in catalysis, the redox-active disulfides (Cys53 and
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Figure 1
Molecular formulae for human and trypanosomal metabolites: 
(a) glutathione disulfide (GSSG) and (b) trypanothione disulfide
(T[S]2). Trypanothione comprises γGlu–Cys–Gly–Spm–Gly–Cys–γGlu
with the suffix I or II to identify separate components and to be
consistent with the nomenclature used previously on GSSG
complexed with human GR [8]. Following reduction by the cognate
enzyme, GSSG is converted to two molecules of the thiol, GSH,
whereas T[S]2 is converted to a single molecule of the dithiol, T[SH]2.
Cys58) and active-site base (His461′) are located at the
bottom of the cleft near the isoalloxazine ring of FAD. As
noted previously [14,17], the disulfide-substrate-binding
site is one of the most ordered parts of the structure, as
indicated by thermal parameters and real-space residuals.
There are no large conformational changes upon binding
T[S]2. A least-squares fit of the native structure with the
protein atoms of the enzyme–substrate complex provides
root mean square (rms) deviations of 0.7 Å for all atoms and
0.25 Å for Cα atoms.
Trypanothione binding
T[S]2 binds asymmetrically in the rigid TR active site
(Figures 3 and 4a). One γGlu–Cys–Gly component (I) is
close to the redox-active disulfides and His461′, residues
that form the catalytic machinery. This segment of the
substrate adopts a U shape, whereas the other tripeptide
moiety, component (II), adopts an extended conforma-
tion. There are 25 amino acid residues implicated in
binding T[S]2 by hydrogen bonding and/or van der Waals
interactions (Figure 4, Table 1). Direct enzyme–substrate
hydrogen bonds involve the functional groups on side-
chains of Glu19 and Tyr111 and the peptide link between
the GlyI and spermidine (Spm) components. A solvent-
mediated link between GlyI N with Ser15 is also appar-
ent, as is a CH•••O hydrogen bond between His461′ Cε1
and γGluII Oδ (Figure 4a). This latter interaction will be
discussed later.
The Spm bridge of T[S]2 is asymmetric and the resolution
of our structure does not enable a clear identification of the
N4-secondary amino group. There are no direct electrostatic
interactions between the charged N4-secondary amine
group of T[S]2 with the enzyme, irrespective of where we
assign N4, so an arbitrary choice was made. Binding of this
part of the substrate is mediated by van der Waals and
cation-pi interactions, with components of a hydrophobic
patch in the TR active site comprising the sidechains of
Leu18, Trp22, Tyr111 and Met114. In the complex formed
between C. fasciculata TR and glutathionylspermidine disul-
fide a hydrogen bond can occur between Sδ of Met113 with
a terminal amino group of the ligand [14]. This interaction
is not possible with T[S]2 because the cyclic nature of this
substrate keeps the amino group of the Spm bridge away
from the corresponding residue in T. cruzi TR, namely
Met114. Nevertheless, Met114 is an important residue as it
contributes to the hydrophobic patch on one side of the
active site. Solvent-accessible areas have been calculated
for the T[S]2 molecules in isolation and when complexed to
provide an estimate of the molecular surface area involved
in binding to the enzyme. This indicates that 87% of the
substrate becomes buried when the complex is formed.
The average area lost is about 850 Å2, which in energy
terms is significant and approximates to a hydrophobicity
component of binding of 85 kJ mol–1 [14].
The human GR–GSSG complex
To fully exploit the differences between TR and GR for
inhibitor design or discovery we need to understand the
molecular basis for the mutually exclusive substrate speci-
ficities. It is necessary to review what is known about the
GR–GSSG structure [8] (PDB entry 1GRA). GSSG in the
active site of human GR and the hydrogen bonds formed
between the substrate and enzyme are shown in Figure 4b.
The γGlu–Cys–Gly (I) component binds at the catalytic
machinery in a V shape, whereas the other tripeptide adopts
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Figure 2
Organisation of the T. cruzi TR dimer. FAD
and T[S]2 molecules are shown as van der
Waals spheres, coloured dark blue and cyan,
respectively. The three distinct domains from
each subunit are coloured differently: the
FAD-binding domain (domain I) is in yellow;
the NADPH-binding domain (domain II) is in
green; and the interface domain is in red. The
dimer interface is indicated by a pink line, and
an arrow points to the disulphide-substrate-
binding site. This figure was composed using
MOLSCRIPT [36] and Raster3D [37].
an extended conformation. A similar asymmetry is observed
for T[S]2 in the active site of TR, as discussed above. A
prominent feature of the active site of human GR is a
cluster of arginines: Arg37, Arg38 and Arg347, which creates
a positively charged GR active site to bind the negatively
charged GSSG. The enzyme–substrate interactions are
dominated by hydrogen bonds formed between the side-
chains of GR and GSSG. Of particular importance are the
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Figure 4
Comparison of enzyme–substrate
interactions. (a) Stereoview of the active site
of TR with bound T[S]2. Selected residues
are shown, labelled with the single-letter
code, and sidechains are coloured according
to their chemistry: basic residues are blue,
acidic residues red, polar residues pink and
hydrophobic residues grey. A similar atom-
colouring scheme to that of Figure 3 is
adopted, except that C atoms are green.
Hydrogen bonds are depicted as thin
continuous lines. Van der Waals surfaces are
shown for residues that create a hydrophobic
patch. Asn23 and Ala344 are discussed in
the text but omitted from the figure because
they do not interact with T[S]2. 
(b) Stereoview of GSSG in the active site of
human GR. Solvent molecules have been
removed for the sake of clarity. This figure
was produced using MOLSCRIPT [36].
Figure 3
Stereoview of the omit Fobs–Fcalc difference
density maps for T[S]2 in an active site of 
T. cruzi TR. The map (green) is contoured at a
1.5σ level. T[S]2 atomic positions are shown
coloured according to atom type: C, black; N,
cyan; O, red; S, yellow. Solvent positions are
represented by blue spheres. This figure was
produced using MOLSCRIPT [36].
strong electrostatic interactions formed between the
arginines at positions 37 and 347 with the GSSG carboxy-
lates of GlyI and γGluI, respectively. Another important
interaction involves the sidechain of Asn117 and the car-
boxylate of GlyII. In the PDB file this sidechain is posi-
tioned with Oδ1 close to a carboxylate oxygen of GlyII
and in the original publication [8] this residue was described
as participating in a solvent-mediated hydrogen-bonding
interaction with the GlyII carboxylate. The solvent mol-
ecule also linked this carboxylate with the guanidinium of
Arg37. Our assessment of the PDB entry is that a switch of
the oxygen and nitrogen sidechain atoms of Asn117 would
produce a direct hydrogen bond between Nδ2 and GlyII
O32 of distance 3.1Å and this is what we depict in Figure
4b. In addition to the direct interactions discussed above
there are numerous solvent-mediated hydrogen-bonding
networks that link the functional groups of GSSG and GR.
The determinants of specificity
TR and GR are mutually exclusive with respect to sub-
strate specificity [10] and this has been ascribed to a com-
bination of steric and electrostatic factors [8,14–17]. The
substrates differ in size and charge but have conserved
γ-glutamylcysteinyl moieties (Figure 1). GSSG is the smaller
of the two and carries a net charge of –2 at physiological pH.
T[S]2 carries a net charge of +1 and a hydrophobic compo-
nent of seven methylene groups on the Spm bridge.
Structural comparisons indicate differences in the orienta-
tion of domains with respect to each other, which influence
the size of the GR and TR active sites [15–17]. Human GR
has a smaller disulfide-substrate-binding site than TR. As a
result, T[S]2 is too large to fit optimally into the GR site
and GSSG is too small to fit optimally into the TR active
site. There are also specific amino acid alterations that
affect both the size and the chemistry of the disulfide-sub-
strate-binding sites. In human GR there are 19 amino acids
implicated in the binding of GSSG, of which 14 are identi-
cal or homologous to residues in TR. These conserved
residues include the catalytic machinery and, as one might
expect, mainly interact with the γ-glutamylcysteinyl com-
ponents of the substrates. The only significant difference
involving this part of each substrate concerns γGluI. In the
human GR–GSSG complex Arg347 interacts directly with
γGluI. In T. cruzi TR this residue is replaced by Ala343,
resulting in the loss of this electrostatic interaction and pro-
viding more freedom for the γGluI component of T[S]2.
There are five residues that interact with GSSG in human
GR that are not conserved in TR: Ala34, Arg37, Ile113,
Asn117 and Arg347 (Figure 4b). The corresponding residues
in T. cruzi TR are Glu19, Trp22, Ser110, Met114 and
Ala344 (Figure 4a); in addition, Arg38 in human GR is
Asn23 in TR. The Arg347 to Ala344 difference has been
discussed above. The locations of the remaining amino
acid substitutions suggest that the substrate discrimination
displayed by GR and TR is determined primarily on one
side of their respective active sites. These substitutions
change the narrow, positively charged and hydrophilic GR
cleft into a wider TR active site with a hydrophobic patch
adjacent to a negative glutamic acid. The positively charged
human GR active site effectively binds the negatively
charged GSSG but would repulse T[S]2. The TR active
site would repulse GSSG with a combination of charge
repulsion and hydrophobic effects.
A protease-like catalytic triad and induced electronic fit
The disulfide oxidoreductases utilise an active-site histi-
dine as the proton donor and acceptor in the catalytic cycle
[7]. In T. cruzi TR this is His461. The imidazole is held in
place with a hydrogen bond formed between Nδ1 and Oε1
of Glu466. Structures of human GR and T. cruzi TR, in
the absence of substrate, have a solvent molecule posi-
tioned to bind to the active-site histidine Nε2 and the
arrangement of functional groups in the Glu–His–Water
assembly mimics that of a serine-protease catalytic triad
[17]. When the substrate is bound, the CysI Sγ atom is
positioned about 3 Å from Nε2 and optimally positioned
to accept a relayed proton.
Investigation of catalytic-triad geometry in the serine pro-
teases highlighted the role that a CH•••O hydrogen bond
might play in fine tuning the chemical properties of the
active-site histidine [18]. The specific interaction involves
the His Cε1 with a mainchain carbonyl group that is always
positioned to influence the catalytic histidine. In the
TR–T[S]2 complex we see a similar CH•••O interaction.
However, the carbonyl-group hydrogen-bond acceptor is
provided by the disulfide substrate and not, as observed in
the proteases, by the protein mainchain. In the TR–T[S]2
complex the distances between His461′ Cε1 and the γGluII
carbonyl Oδ are 2.9 and 3.3 Å in active sites A and B,
respectively. This interaction is also present in human GR
when complexed with GSSG. Such an interaction, with the
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Table 1
The interacting residues of T[S]2 and TR.
Number of contacts
T[S]2
residue A site B site Trypanothione-reductase residues
γGluI 10 24 Pro336, Ile339, Gly459′,His461′, 
Glu466′
CysI 8 5 Val54, Tyr111, Thr335, Ile339, His461′
GlyI 7 8 Ser15, Leu18, Tyr111, Ile339
Spm 18 14 Leu18, Glu19, Trp22, Ser110, Tyr111
γGluII 25 20 Val54, Val59, Lys62, Phe396, Lys399,
His461′, Pro462′, Thr463′, 
Ser464′, Glu466′, Glu467′
CysII 5 5 Val59, Ile107, His461′
GlyII 1 0 Ile107
The number of contacts, excluding hydrogen bonds, with a distance
restriction of 4.0 Å are listed; ′ signifies a residue from the partner subunit.
resultant polarisation of the Cε1–H bond, may serve to sta-
bilise the positive-charge distribution on the protonated
histidine that is required for the catalytic function. TR and
GR thus appear to be fine tuned for catalysis. Enzyme–
ligand interactions position the substrates, which, in turn,
prime the active-site base for catalysis. We term this elec-
tronic induced fit — the active centre is itself activated by
the substrate it processes. This would contribute to the sub-
strate specificity of TR and GR because each enzyme can
only be optimally aligned for catalysis once the cognate sub-
strate is in position. Such a structural feature may be an
important consideration in the development of transition
state analogue inhibitors of TR.
Structure-based inhibitor discovery
The molecular detail of the TR–T[S]2 complex provides
definition of the shape and electrostatic nature of the
enzyme active site, the conformation of the substrate, details
of the enzyme–ligand interactions and a structural expla-
nation for the substrate discrimination displayed by TR
and GR. This information is invaluable for structure-based
identification of inhibitors. A difficulty with respect to TR
is the size of both the active site and the substrate. T[S]2
extends almost 17 Å in the longest dimension. To simplify
the problem we concentrated on the interaction of the
polyamine component of T[S]2 with the hydrophobic patch
and Glu19 of the TR active site I, which is where the
major differences occur between TR and GR. The sper-
midine–carbonyl conjugate was used as a search fragment
in the Cambridge Structural Database (CSD [19]) to iden-
tify a library of possible inhibitors. Two natural products,
cadabacine (CSD entry FACWAH [20]) and lunarine (entry
LUNARB10 [21]; Figure 5a) were selected for further
investigation on the basis of several criteria. Firstly, these
compounds have the spermidine moiety bound at either
end by an amide group. This feature is shared with T[S]2,
and represents a key portion of the substrate with respect
to TR specificity in addition to being an extension of the
search template. Secondly, the molecules are cyclic and of
comparable dimensions to T[S]2, with a suitable electronic
structure to impart some rigidity to the ring system. Thirdly,
the size and chemistry of cadabacine and lunarine sug-
gested that they would be unlikely to inhibit human GR.
Coordinates were retrieved from the CSD and positioned
into the TR active site using the program DOCK 3.0 [22].
A shape descriptor of the active site was used to derive pos-
sible orientations of the molecules within it. The program
GRID [23] was used to characterise the electrostatic prop-
erties of the TR cleft and this allowed us to identify and
remove unfavourable orientations. The remaining arrange-
ments of these molecules in the active site indicated a con-
served placement of the spermidine components, enabling
interaction with the hydrophobic patch, and a reasonable
fit of the small molecules into the TR active site. We made
no attempt to optimise or manipulate the fit of the mol-
ecules in the enzyme active site. One of the orientations of
lunarine, selected arbitrarily, in the TR disulfide-substrate-
binding cleft is presented in Figure 5b. The modelling
suggested that these natural products could be selective
inhibitors of TR and we sought to validate this hypothesis
experimentally. Although unable to obtain a sample of
cadabacine, we did obtain lunarine and characterised its
inhibition kinetics against T. cruzi TR and human GR.
Lunarine was found to be a selective inhibitor of TR;
human GR was not significantly inhibited by 500 µM
lunarine under conditions that inhibit TR by 97%. This
result confirmed our predictions. Unexpectedly, the inhibi-
tion pattern does not conform to that of a simple competi-
tive inhibitor in that it shows time dependence involving






























A novel inhibitor of trypanothione reductase. (a) Molecular formula of lunarine. (b) Stereoview showing a model of lunarine (magenta) in an active
site of T. cruzi TR. For comparison, a ‘ghostly’ depiction of T[S]2 is provided. The view and solvent positions are as in Figure 4a. This figure was
produced using MOLSCRIPT [36].
the NADPH-reduced (EH2) form of the enzyme. Inhibi-
tion is both time- and concentration-dependent and can be
fitted to a double exponential decay equation (Figure 6).
Within experimental error, the rate constant for the second
phase approximates the rate of inactivation by NADPH in
the absence of lunarine. In contrast, the rate constant for
the first phase is hyperbolic with respect to inhibitor con-
centration from which an apparent Ki of 144 ± 30.5 µM and
kinact of 0.116 ± 0.009 min–1 can be derived. We conclude
that inhibition most likely involves a reversible multi-step
mechanism of the type: 
E + I ⇔ EI ⇔ E*I
where EI represents a non-covalent Michaelis-type enzyme
inhibitor intermediate complex and E*I a subsequent cova-
lent complex between lunarine and the two electron-
reduced form of TR. This mode of inhibition of TR has
been observed before, in particular with arsenical drugs that
are in clinical use [24]. The modest Ki of 144 µM for lunar-
ine is encouraging when compared to a binding constant
of approximately 40 µM for T[S]2 and allows considerable
scope for improvement. A useful lead compound should
be amenable to chemical modification and inspection of
the lunarine structure (Figure 5a) indicates at least two
positions where nucleophilic attack (Michael addition) can
occur to permit synthetic modifications of the molecular
framework. We had not predicted the possibility of a cova-
lent link between lunarine and the reduced form of TR in
advance of the kinetic studies. The observation provides
further support for the use of these alkaloids as lead com-
pounds and even suggests that components of lunarine
might be suitable for the development of suicide inhibitors
of a range of disulfide oxidoreductases. If, as is likely,
Michael addition has occurred between lunarine and TR,
and the model presented in Figure 5b is correct, then addi-
tion at C13 would be favoured over C25.
Concluding remarks
An important aspect of the pharmaceutical industries’
research effort is the hunt for naturally occurring molecules
with biological activity. This is based on the historical
lesson that many therapeutic agents are natural products, or
derivatives thereof, identified in part on the basis of folk
lore. Important examples are quinine from Chinchona bark
and artemesinin from Chinese herbal extracts [3]. Both of
these compounds are used for the treatment of malaria,
which is a serious protozoan-parasite infection. Our search
for new inhibitors of TR has identified two alkaloids
extracted from plants that are also used in folk medicine
[e.g. 25]. Cadabacine is derived from a shrub (Cadaba
farinosa) grown throughout South and Eastern Africa, the
Middle East and Asia. Lunarine is derived from the common
European garden plants Lunaria biennis and L. rediviva.
Lunarine has been confirmed as a novel inhibitor of T. cruzi
TR and this family of natural products now provides a
series of promising lead compounds for further experiments
designed to improve inhibition properties in the search for a
molecule of medicinal value.
Biological implications
Several species of protozoa of the order Kinetoplastida,
suborder Trypanosomatina, are the causal agents of a
variety of serious tropical diseases afflicting humans and
livestock. New and improved anti-trypanosomal drugs
are urgently sought because current therapies are inade-
quate as a result of the low efficacy and high toxicity of
available drugs. Vaccines have not been forthcoming
and the problem is compounded by the ability of the par-
asites to develop drug resistance.
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Figure 6
Inhibition of trypanothione reductase by
lunarine. (a) Residual activity as a function of
lunarine concentration: no drug (triangles);
plus drug: 62.5 µM, (open circles); 125 µM,
(closed circles); 250 µM, (open squares);
500 µM, (closed squares). (b) Observed rate
of inactivation as a function of lunarine
concentration. Bars indicate the standard
error for each data set.
The enzyme trypanothione reductase (TR) is unique to
the Trypanosomatina, where it is a key component of
the parasites’ antioxidant defence systems. TR has been
validated as a target for the development of new anti-try-
panosmal drugs by molecular genetics methods. As a
component of a structure-based approach to drug identi-
fication, we have characterised the three-dimensional
structure of TR from one of the most important human
parasites, Trypanosoma cruzi, in complex with one of the
physiological substrates, trypanothione. The complex
provides structural detail that explains enzyme speci-
ficity and characterises the binding site for the disulfide
substrate in terms of van der Waals interactions, and
hydrogen-bond donors and acceptors. The substrate
provides templates for searching chemical libraries in an
attempt to find molecules able to bind in the active site
and function as inhibitors. The enzyme active site pro-
vides a target for characterisation using computational
methods that suggest the electrostatic and steric criteria
that prospective ligands must fulfil. Our utilisation of the
model in database searches and molecular modelling has
identified the polyamine-bearing alkaloids, cadabacine
and lunarine, as candidates for inhibition trials. Lunar-
ine has been confirmed as a selective inhibitor of T. cruzi
TR, but it essentially has no effect on the homologous
human enzyme, glutathione reductase. These natural
products now provide a series of lead compounds for
further experiments designed to improve inhibition prop-
erties in the search for a molecule of medicinal value.
Materials and methods
Purification, crystallization and data collection
Recombinant enzymes were purified from E. coli using methods previ-
ously described [26]. Trypanothione was purchased from Bachem,
Germany. Co-crystallization of TR and T[S]2 was achieved using condi-
tions previously reported [27]. The best crystals were obtained when a
ratio of monomer:substrate of approximately 1:0.9 was used. Yellow
rods in space group P43, with a = b = 93.33, c = 157.14 Å grew in
several days. These crystals are isomorphous with the native structure
and contain a homodimer in the asymmetric unit. Diffraction data were
recorded at 4°C from a crystal of dimensions 0.2 × 0.2 × 1.1 mm,
mounted in a capillary with mother liquor, on station PX9.6 (λ 0.92 Å /
Mar Research image plate) at the Synchrotron Radiation Source at
Daresbury Laboratory. Data were processed using the MOSFLM [28]
and CCP4 programs [29]. The data comprised 142,903 Iσ(I) mea-
surements of 45,818 unique reflections (Rsym 7.5%) to a resolution of
2.4 Å. This represents 87.4% coverage.
Structure refinement
The starting model was the native T. cruzi TR structure [17]. Refine-
ment was carried out with the program X-PLOR [30] using the Engh
and Huber dictionary for restraints [31] and similar protocols as those
employed in the native structure. Map calculations used CCP4 pro-
grams [29], computer graphics checking and analysis used FRODO
[32] and O [33]. The stereochemical quality of the model was moni-
tored with PROCHECK [34]. At an early stage of the analysis we
observed distinct conformations for γGluI. In one active site (A) there
are a number of solvent-mediated contacts to residues on the interface
domain; in the other active site γGluI is more buried, forms an increased
number of van der Waals interactions with the enzyme and participates
in hydrogen bonds to both mainchain and sidechain atoms of the inter-
face domain. The substrate was gradually built into difference maps
during the refinement, incorporated into the calculations and checked
with the use of omit maps. Solvent positions were treated as oxygens
and checked after each round of refinement. Solvents in the disulfide-
substrate-binding site were only included in refinement when the sub-
strate had been completely modelled.
Refinement converged with an R factor of 20.9% for 41,129 reflections
with F > σF in the range 8.0–2.4 Å resolution. The final model com-
prises residues 2–486 of subunit A, 9–486 of subunit B (7459 non-
hydrogen atoms), two FAD molecules (106 atoms), 409 waters and
two molecules of T[S]2 (96 atoms). The model has rms deviations in
bond lengths, bond angles, dihedral and improper angles of 0.011 Å,
2.7°, 24.5° and 1.8°, respectively. Average thermal parameters are
29.4 and 35.7 Å2 for all protein atoms of subunits A and B, respec-
tively; 15.3 and 25.0 Å2 for the FAD groups; 73.5 and 73.1 Å2 for sub-
strate in binding sites A and B. Solvent molecules have an average
thermal parameter of 47.5 Å2. The substrate disulfide electron density
in omit maps has been compared to the enzyme disulfide peak heights
and suggests an occupancy of approximately 0.5 for the substrate. We
maintained unit occupancy of the substrate atoms and let the thermal
parameters account for any lower value. Nuclear magnetic resonance
spectroscopy indicates that T[S]2 displays a considerable degree of
conformational flexibility [35]. We suggest that a combination of partial
occupancy and flexibility explains the observed thermal parameters. A
Ramachandran plot [34] has 90.8% of residues in most favoured
regions and a further 8.6% in allowed regions. Five residues are in dis-
allowed regions: Lys4A, Lys305A, Ala263B, Phe45A and Phe45B. The
phenylalanines are in well-defined loops with the mainchains held in a
strained conformation. 
Inhibitor studies
Enzymes were stored as suspensions in ammonium sulphate and dial-
ysed against assay buffer before use. TR (3 nM) was assayed using a
Beckman DU640 spectrophotometer in 40 mM (K+) HEPES, pH 7.5,
1 mM EDTA and 0.27 mM NADPH in a total volume of 0.5 ml at 26°C,
followed by the addition of T[S]2 (0.1 mM). GR (24 nM) was assayed in
a similar manner, but in 40 mM (K+) HEPES, pH 7.0, 1 mM EDTA,
80 mM KCl and 0.27 mM NADPH followed by the addition of 0.1 mM
GSSG. Enzyme mixtures were preincubated with NADPH (5 min at
26°C) before the addition of varying concentrations of lunarine (stock
solution 12.5 mM in dimethylsulphoxide). At varying times following the
addition of inhibitor the reaction was initiated by the addition of the
appropriate substrate. As a result of the interfering absorbance of
lunarine at 340 nm, oxidation of NADPH was monitored at 366 nm
using an extinction coefficient of 3300 M–1 cm–1 and all experiments
were performed in triplicate.
Accession numbers
Structure factors and coordinates have been deposited in the PDB and
assigned accession numbers R1BZLSF and 1BZL, respectively.
Acknowledgements
The work was funded by the Wellcome Trust, an Overseas Research Schol-
arship to YZ, BBSRC/EPSRC and the Daresbury Synchrotron Laboratory.
We acknowledge the EPSRC-funded Chemical Database Service at Dares-
bury. We thank C Poupat for the gift of lunarine, S Bailey and R Nuttall for
discussions, S McSweeney and P Rizkallah for support at Daresbury and
referees for constructive criticisms.
References
1. Moncayo, A. (1993). Chagas’ disease. In Tropical Disease Research;
Progress 1991-92, pp. 67-76. World Health Organisation, Geneva.
2. de Castro, S. (1993). The challenge of Chagas’ disease
chemotherapy: an update of drugs assayed against Trypanosoma
cruzi. Acta Trop. 53, 83-98.
3. Schirmer, R.H., Muller, J.G. & Krauth-Siegel, R.L. (1995). Disulfide-
reductase inhibitors as chemotherapeutic agents: the design of drugs
for trypanosomiasis and malaria. Angew. Chem. Int. Ed. Engl. 34,
141-154.
88 Structure 1999, Vol 7 No 1
4. Verlinde, C.L.M.J. & Hol, W.G.J. (1994). Structure-based drug design:
progress, results and challenges. Structure 2, 577-587.
5. Marton, L.J. & Pegg, A.E. (1995). Polyamines as targets for
therapeutic intervention. Annu. Rev. Pharmacol. Toxicol. 35, 55-91.
6. Dolphin, D., Poulson, R. & Avramovic, O. (1989). Glutathione;
Chemical, Biochemical and Medical Aspects. John Wiley & Sons,
New York, USA.
7. Karplus, P.A. & Schulz, G.E. (1989). Substrate binding and catalysis
by glutathione reductase as derived from refined enzyme:substrate
crystal structures at 2.0 Å resolution. J. Mol. Biol. 210, 163-180.
8. Fairlamb, A.H. & Cerami, A. (1992). Metabolism and functions of
trypanothione in the kinetoplastida. Annu. Rev. Microbiol. 46, 695-729. 
9. Henderson, G.B., Fairlamb, A.H., Ulrich, P. & Cerami, A. (1987).
Substrate specificity of the flavoprotein trypanothione disulfide
reductase from Crithidia fasciculata. Biochemistry 26, 3023-3027.
10. Dumas, C., et al., & Papadopoulou, B. (1997). Disruption of the
trypanothione reductase gene of Leishmania decreases its ability to
survive oxidative stress in macrophages. EMBO. J. 16, 2590-2598.
11. Tovar, J., Cunningham, M.L., Smith, A.C., Croft, S.L. & Fairlamb, A.H.
(1998). Down-regulation of Leishmania donovani trypanothione
reductase by heterologous expression of a trans-dominant mutant
homologue: effect on parasite intracellular survival. Proc. Natl Acad.
Sci. USA 95, 5311-5316.
12. Tovar, J., Wilkinson, S., Mottram, J.C. & Fairlamb, A.H. (1998)
Evidence that trypanothione reductase is an essential enzyme in
Leishamania by targeted replacement of the tryA gene locus. Mol.
Microbiol. 29, 653-660.
13. Stoll, V.S., Simpson, S.J., Krauth-Siegel, R.L., Walsh, C.T. & Pai, E.F.
(1997). Glutathione reductase turned into trypanothione reductase:
structural analysis of an engineered change in substrate specificity.
Biochemistry 36, 6437-6447.
14. Bailey, S., Smith, K., Fairlamb, A.H. & Hunter, W.N. (1993). Substrate
interactions between trypanothione reductase and N1-
glutathionylspermidine disulfide at 0.28nm resolution. Eur. J. Biochem.
213, 67-75.
15. Kuriyan, J., et al., & Henderson, G.B. (1991). X-ray structure of
trypanothione reductase from Crithidia fasciculata at 2.4 Å resolution.
Proc. Natl Acad. Sci. USA 88, 8764-8768.
16. Hunter, W.N., et al., & Fairlamb, A.H. (1992). Active site of
trypanothione reductase; a target for rational drug design. J. Mol. Biol.
227, 322-333.
17. Zhang, Y., Bond, C.S., Bailey, S., Cunningham, M.L., Fairlamb, A.H. &
Hunter, W.N. (1996). The crystal structure of trypanothione reductase
from the human pathogen Trypanosoma cruzi at 2.3 Å resolution.
Protein Sci. 5, 52-61.
18. Derewenda, Z.S., Derewenda, U. & Kobos, P.M. (1994). His Cε-
H...O=C< hydrogen bond in the active site of serine hydrolases. J.
Mol. Biol. 241, 83-93.
19. Allen, F.H. & Kennard, O. (1993). 3D search and research using the
Cambridge Structural Database. Chem. Design. Auto. News. 8 ,
130-137.
20. Ahmed, V.U., Amber, A., Arif, S., Chen, M.H.M. & Clardy, J. (1985).
Cadabacine, an alkaloid from Cadaba farinosa. Phytochemistry. 24,
2709-2711.
21. Tamura, C. & Sim, G.A. (1970). Molecular conformations. Part X. A
skew boat cyclohexanone: X-ray analysis of lunarine hydrobromide
hydrate. J. Chem. Soc. (B) 991-995.
22. Kuntz, I.D. (1992). Structure-based strategies for drug design and
discovery. Science 257, 1078-1082.
23. Goodford, P.J. (1985). A computational procedure for determining
energetically favorable binding sites on biologically important
macromolecules. J. Med. Chem. 28, 849-857. 
24. Cunningham, M.L., Zvelebil, M.J.J.M. & Fairlamb, A.H. (1994).
Mechanism of inhibition of trypanothione reductase and glutathione
reductase by trivalent organic arsenicals. Eur. J. Biochem. 221, 
285-295.
25. Breyer-Brandwijk, M.G. & Watt, J.M. (1962). The Medicinal and
Poisonous Plants of Southern and Eastern Africa. (2nd edn), E. & S.
Livingston Ltd, Edinburgh, UK.
26. Borges, A., Cunningham, M.L., Tovar, J. & Fairlamb, A.H. (1995). Site-
directed mutagenesis of the redox-active cysteines of Trypanosoma
cruzi trypanothione reductase. Eur. J . Biochem. 228, 745-752.
27. Zhang, Y., et al., & Hunter, W.N. (1993). Trypanosoma cruzi
trypanothione reductase, crystallization, unit cell dimensions and
structure solution. J .Mol. Biol. 233, 1217-1220.
28. Leslie, A.G.W. (1993). Joint CCP4 and ESF-EACMB Newsletter on
Protein Crystallography. Daresbury Laboratory, Warrington, UK.
29. Collaborative Computational Project Number 4. (1994). The CCP4
suite: programs for protein crystallography. Acta Cryst. D 50, 760-763.
30. Brünger, A.T. (1990). X-PLOR (V 2.2) Manual. Howard Hughes
Medical Institute, Yale University.
31. Engh, R.A. & Huber, R. (1991). Accurate bond and angle parameters
for X-ray protein-structure refinement. Acta Cryst. A 47, 392-400.
32. Jones, T.A. (1985). FRODO-A graphic model building and refinement
system for macromolecules. Methods Enzymol. 115, 157-171.
33. Jones, T.A., Zou, J.Y., Cowan, S.W. & Kjeldgaard, M. (1991). Methods
for building protein models in electron density maps and the location
of errors in these models. Acta Cryst. A 47, 110-119.
34. Laskowski, R.A., MacArthur, M.W., Moss, D.S. & Thornton, J.M.
(1993). PROCHECK: a program to check the stereochemical quality
of protein structures. J. Appl. Cryst. 26, 283-291.
35. Henderson, G.B., Glushka, J., Cowburn, D. & Cerami, A. (1990).
Synthesis and NMR characterisation of the trypanosomatid metabolite,
N1, N8-bis(glutathionyl)spermidine disulfide (trypanothione disulfide).
J. Chem. Soc. Perkin Trans. 1, 911-914.
36. Kraulis, P.J. (1991). MOLSCRIPT: a program to produce both detailed
and schematic plots of protein structures. J. Appl. Cryst. 24, 946-950.
37. Merritt, E.A. & Murphy, M.E.P. (1994). Raster3d, a program for
photorealistic molecular graphics. Acta Cryst. D 50, 869-873.
Research Article  Trypanosoma cruzi trypanothione reductase Bond et al.    89
Because Structure with Folding & Design operates a
‘Continuous Publication System’ for Research Papers, this
paper has been published on the internet before being printed
(accessed from http://biomednet.com/cbiology/str). For
further information, see the explanation on the contents page.
